239 related articles for article (PubMed ID: 8097480)
1. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
[TBL] [Abstract][Full Text] [Related]
2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
3. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
6. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
7. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion.
de Herder WW; Krenning EP; Malchoff CD; Hofland LJ; Reubi JC; Kwekkeboom DJ; Oei HY; Pols HA; Bruining HA; Nobels FR
Am J Med; 1994 Apr; 96(4):305-12. PubMed ID: 8166148
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
11. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
15. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
16. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
[TBL] [Abstract][Full Text] [Related]
17. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
18. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for somatostatin and its analogs in Cushing's syndrome?
de Herder WW; Lamberts SW
Metabolism; 1996 Aug; 45(8 Suppl 1):83-5. PubMed ID: 8769391
[TBL] [Abstract][Full Text] [Related]
20. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion.
Shimon I; Rubinek T; Hadani M; Alhadef N
J Endocrinol Invest; 2004 Sep; 27(8):721-7. PubMed ID: 15636423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
